预约演示

OncoX inks licensing deal worth over $26m for NSCLC therapy

2024-04-18

交易

引进/卖出临床2期临床3期临床1期临床结果

BLEX 404 is the β-glucan extracted from the dry fruit body of Grifola frondosa (maitake mushrooms). Image Credit: asch_asch / Shutterstock.

BLEX 404 ABVC Biβ-glucanhas sold the rights to its botanical drug extract therapy, BLEX 404, for the treatment of non-small cell lung cancer (NSCLC) to the dietary supplements company OncoX.

Under theABVC BioPharmaVC will receive an aggregate licence fee of $12.5m as eitherBLEX 404 stocks of OncoX. Furthnon-small cell lung cancer (NSCLC)ntitled to a milestone-based payment of $1.25m and 5% royalties on net sales of BLEX-404 for up to $12.5m.

BLEX 404 is the β-gluABVCextracted from the dry fruit body of Grifola frondosa (maitake mushrooms), whOncoXre native to China, Europe and North America. The safety of the maitake mushroom extract has been evaluated in two studieBLEX-404ase I/II trial involving postmenopausal patients with breast cancer following remission and a Phase II trial in patients with myelodysplastic syndrome (MDS). The maitake extract was well tolerated in both trials and immunological response was also observed.

BLEX 404ood and β-glucaninistration (FDA) cleared the investigational new drug application (IND) to start an open-label Phase I/II trial evaluating the safety and tolerability of BLEX 404 in combination with chemotherapy in patients with advanced inoperable or metastatic EGFR-mutated NSCLCbreast cancer2022. As per the licencing agreement, ABVC will bear responmyelodysplastic syndrome (MDS)lopmenmaitake extract

ABVC’s Food and Drug Administration (FDA)apies derived from plant and fungal extracts. The company’s lead assets ABV-1504 and ABV-1505 are plant-based norepinephrine transporter (BLEX 404ibitors. In November 2023, ABVC signed a global licensing agreement with AiBtl for both ABV-1504 and ABV-1505.ABVC BLEX 404

ABVCAlso:ABV-1504 ABV-1505 ABVC AiBtl ABV-1504 ABV-1505

Clearmind licenses psychedelic compounds for mental disorders

Clearminds secures funds to advance oncolyticmental disordersapy

The company is currently conducting an interim analysis of the Phase IIb trial (NCT05202327) of ABV-1504 in patients with attention deficit hyperactivity disorder (ADHD), with the results expected in Q2 this year, as per the ABVC’s 2023 financials. ABVC is also planning an end-of-Phase II meeting with the US FDA to finalise the protocol for the Phase III trial for ABV-1504 in patients with major depressive disorder.

Theolyticslogy therapies in ABVC’s pipeline include ABV-1501 for the treatment of triple-negative breast cancer, ABV-1702 for treating MDA, and ABV-1703 for the treatment of pancreatic cancer. All three therapies contain maitake mushroom extract.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构